ReviewObesity science & practice2023
Obesity and chronic kidney disease: A current review.
Review in Obesity science & practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Ultra-processed foods and risk of declined renal function: a dose-response meta-analysis of 786,216 participants.Journal of health, population, and nutrition · 2025Pooled it
- The risk of chronic kidney disease or proteinuria with long or short sleep duration: a systematic review and meta-analysis of cohort studies.Clinical and experimental nephrology · 2025Pooled it
- Lost and not found: randomized controlled trial of cognitive behavioral therapy for weight-loss in patients with chronic kidney disease.Journal of behavioral medicine · 2025Trial
- Decline and Resurgence of Cardiovascular-Kidney-Metabolic Syndrome-Related Deaths Involving Malnutrition in the United States, 1999 to 2023.Journal of the American Heart Association · 2026Article
- Baseline and Follow-Up Association between Adiposity and Renal Function: Data from the ILERVAS Cohort.Obesity facts · 2026Article
- Update on Obesity and Its Relationship to Atherosclerotic Cardiovascular Disease and Associated Risk Factors.Journal of clinical medicine · 2026Review
- Practical recommendations for treating patients with chronic kidney disease in Australia: a multidisciplinary approach.Internal medicine journal · 2026Article
- Irisin-Driven AMPK-PGC-1α Activation Underlies the Renoprotective Effects of Swimming Exercise in Obesity-Induced Kidney Injury.Biomolecules · 2026Article
- Effectiveness of a school-based obesity control program among adolescents in Makkah: A pretest-posttest intervention study.Journal of Taibah University Medical Sciences · 2026Article
- Kidney dysfunction and its associated factors among people living with HIV on antiretroviral therapy in rural Rwanda: a cross-sectional study.BMC infectious diseases · 2026Article
- Obesity-related glomerulopathy, A growing kidney burden in the obesity pandemic.Clinical and experimental nephrology · 2026Review
- Early Detection of Chronic Kidney Disease in Men Using Lifestyle and Demographic Indicators: A Machine Learning Approach for Primary Healthcare Settings.Healthcare (Basel, Switzerland) · 2026Article
- Article
- Eplerenone improves kidney function and cardiac performance in obese male mice.Diabetic medicine : a journal of the British Diabetic Association · 2026Article
- Combining Ketoacid Analog Supplemented Low-Protein Diets with Sodium-Glucose Cotransporter-2 Inhibitors for Patients with Diabetic Kidney Disease.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- Quantitative assessment of renal and perirenal adipose tissue distribution at 5 T: a feasibility study.BMC medical imaging · 2025Article
- The relation between tirzepatide and adverse cardiovascular events or renal adverse events: a meta-analysis based on randomized controlled trials.Diabetology & metabolic syndrome · 2025Article
- Hesperidin Reverses Oxidative Stress-Induced Damage in Kidney Cells by Modulating Antioxidant, Longevity, and Senescence-Related Genes.Biomedicines · 2025Article
- Global burden and epidemic trends of chronic kidney disease attributable to high body mass index: insights from the Global Burden of Disease Study 2021.Renal failure · 2025Article
- Cardio-kidney-metabolic (CKM) framework: A nephrologist's perspective.Archives of endocrinology and metabolism · 2025Review
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Obesity poses significant challenges to healthcare globally, particularly through its bi-directional relationship with co-morbid metabolic conditions such as type 2 diabetes and hypertension. There is also emerging evidence of an association between obesity and chronic kidney disease (CKD) which is less well characterized. Methods: A literature search of electronic libraries was conducted to identify and present a narrative review of the interplay between obesity and CKD. Findings: Obesity may predispose to CKD directly as it is linked to the histopathological finding of obesity-related glomerulopathy and indirectly through its widely recognized complications such as atherosclerosis, hypertension, and type 2 diabetes. The biochemical and endocrine products of adipose tissue contribute to pathophysiological processes such as inflammation, oxidative stress, endothelial dysfunction, and proteinuria. The prevention and management of obesity may prove critical in counteracting both the development and advancement of CKD. Moreover, measures of abdominal adiposity such as waist circumference, are generally associated with worse morbidity and mortality in individuals receiving maintenance hemodialysis. Conclusion: Obesity is a risk factor for the onset and progression of CKD and should be recognized as a potential target for a preventative public health approach to reduce CKD rates within the general population. Future research should focus on the use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors in patients with CKD and obesity due to their multi-faceted actions on major outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.